Drug Trial News

RSS

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Durvalumab shows tolerable surgical safety profile in patients with resectable NSCLC

Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLC

The oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

September 7th, 2023, the University of Birmingham and Acticor Biotech announce the full regulatory approval of LIBERATE clinical study.

9 Sep 2023

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Alzheimer's disease is the most common cause of dementia that affects more than 6.5 million Americans, according to the Alzheimer's Association.

8 Sep 2023

Broad-spectrum antibiotics linked to higher sepsis risk in neonates

A preprint presents evidence for the hypothesis that neonatal sepsis is linked to prenatal antibiotics.

7 Sep 2023

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

The safety, timing, magnitude, and durability of the antidepressant psilocybin on patients with major depressive disorders.

4 Sep 2023

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

1 Sep 2023

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

From AMGEN 1 Sep 2023

UQ-led clinical trial to test the effectiveness of diabetes drug for polycystic kidney disease

Patient recruitment is underway for a University of Queensland-led clinical trial to test the effectiveness of a diabetes drug to slow the progression of polycystic kidney disease (PKD).

30 Aug 2023

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.

30 Aug 2023

Higher dose and shorter treatment of key antibiotic proven to be safe for TB patients

A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London and results published in NEJM Evidence.

29 Aug 2023

ARAMIS trial finds no benefit of anakinra in acute myocarditis

The largest randomized controlled trial of patients with acute myocarditis has found that anakinra is safe but does not reduce complications. The late breaking research presented in a Hot Line session today at ESC Congress 2023.

29 Aug 2023

Early initiation of dapagliflozin in acute decompensated heart failure does not improve diuretic efficiency

Early initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in hospitalized patients with acute decompensated heart failure (ADHF), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

29 Aug 2023

Acoramidis shows potential to be effective, safe treatment for transthyretin amyloid cardiomyopathy

Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

First oral treatment for Lipoprotein(a) shows significant cholesterol reduction

A new drug offers a breakthrough world first treatment for Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack and stroke, announced today by study lead Professor Stephen Nicholls, Director of the Monash University's Victorian Heart Institute and Victorian Heart Hospital.

28 Aug 2023

Study shows benefit of traditional Chinese medicine for heart failure

The traditional Chinese medicine qiliqiangxin reduces hospitalization for heart failure and cardiovascular death in patients with heart failure and a reduced ejection fraction (HFrEF), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

NOAH-AFNET 6 trial: Oral anticoagulation not recommended for patients with atrial high rate episodes

Blood thinners (anticoagulants) cause bleeding without preventing stroke in patients with atrial high rate episodes (AHRE), but without electrocardiogram (ECG)-diagnosed atrial fibrillation, according to late breaking research presented in a Hot Line session today at ESC Congress 2023 and simultaneously published in the New England Journal of Medicine.

25 Aug 2023

FDA approves more drugs based on single trials and less public disclosure of results

The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent studies from Oregon State University found.

24 Aug 2023

Stem cell patch for treating macular degeneration to enter phase 2b clinical trial

A stem cell patch developed by USC researchers for patients with macular degeneration will soon be tested in a phase 2b clinical trial.

24 Aug 2023

Previous
1
...
7
8
9
10
11
12
13
...
1135
Next

Drug Trial News

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Durvalumab shows tolerable surgical safety profile in patients with resectable NSCLC

Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLC

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Broad-spectrum antibiotics linked to higher sepsis risk in neonates

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

UQ-led clinical trial to test the effectiveness of diabetes drug for polycystic kidney disease

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Higher dose and shorter treatment of key antibiotic proven to be safe for TB patients

ARAMIS trial finds no benefit of anakinra in acute myocarditis

Early initiation of dapagliflozin in acute decompensated heart failure does not improve diuretic efficiency

Acoramidis shows potential to be effective, safe treatment for transthyretin amyloid cardiomyopathy

First oral treatment for Lipoprotein(a) shows significant cholesterol reduction

Study shows benefit of traditional Chinese medicine for heart failure

NOAH-AFNET 6 trial: Oral anticoagulation not recommended for patients with atrial high rate episodes

FDA approves more drugs based on single trials and less public disclosure of results

Stem cell patch for treating macular degeneration to enter phase 2b clinical trial

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News